NCT05764538RecruitingPhase 2
DAOIB for the Treatment of Brain Fog
DAOIB for the Treatment of Cognitive Impairment Induced by COVID-19 -An Open Trial
Source: ClinicalTrials.gov · Last updated 23 Oct 2026
Brief summary (registry, in English)
This is a 24-week open trial. We will enroll long-COVID patients with cognitive impairments. All patients will receive DAOIB for 24 weeks. We will assess the patients every 8 weeks during the treatment period (weeks 0, 8, 16, and 24). We hypothesize that DAOIB treatment will be beneficial in improving the cognitive function, mood symptoms, global functioning and quality of life in long-COVID patients with cognitive impairments.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 28 Feb 2023
- Start date
- 27 Feb 2023
- Primary completion date
- Jun 2027
- Lead sponsor
- Chang Gung Memorial Hospital
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT05764538
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 40
- From 27 Feb 2023 to the primary completion date, Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- history of significant cerebrovascular disease
- major neurological, psychiatric or medical conditions other than long COVID-induced cognitive impairments
Other
- Hachinski Ischemic Score \> 4
- memantine use (memantine is an NMDAR partial antagonist)
- substance (including alcohol) abuse or dependence
- delusion, hallucination or delirium symptoms
- severe visual or hearing loss
- inability to follow the protocol
Who the study is looking for
- "post-COVID-19 condition" defined by WHO (symptoms present at three months after SARS-CoV-2 infection and last for at least 2 months which cannot be explained by an alternative diagnosis)(Cabrera Martimbianco, Pacheco et al. 2021) and COVID-induced cognitive impairments
- physically healthy and have all laboratory assessments (including urine/blood routine, biochemical tests, and electrocardiograph) within normal limits
- have sufficient education to communicate effectively and are capable of completing the assessments of the study
Age in the registry: 18 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kaohsiung Chang Gung Memorial Hospital Coordinator of this site? Confirm its status | Kaohsiung City | Taiwan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.